AMN Healthcare Services (NYSE:AMN – Get Free Report) and Co-Diagnostics (NASDAQ:CODX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.
Profitability
This table compares AMN Healthcare Services and Co-Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AMN Healthcare Services | -10.75% | 11.09% | 3.34% |
| Co-Diagnostics | -6,347.34% | -70.26% | -61.19% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for AMN Healthcare Services and Co-Diagnostics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AMN Healthcare Services | 3 | 1 | 4 | 0 | 2.13 |
| Co-Diagnostics | 1 | 1 | 1 | 1 | 2.50 |
Volatility & Risk
AMN Healthcare Services has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.
Institutional & Insider Ownership
99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 0.9% of AMN Healthcare Services shares are owned by company insiders. Comparatively, 5.4% of Co-Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares AMN Healthcare Services and Co-Diagnostics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AMN Healthcare Services | $2.72 billion | 0.22 | -$146.98 million | ($7.19) | -2.21 |
| Co-Diagnostics | $3.91 million | 5.47 | -$37.64 million | ($0.99) | -0.35 |
Co-Diagnostics has lower revenue, but higher earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
Co-Diagnostics beats AMN Healthcare Services on 9 of the 15 factors compared between the two stocks.
About AMN Healthcare Services
AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions. The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. The Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, and outsourced solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists. It offers its services under the brands, including AMN Healthcare, Nursefinders, HealthSource Global Staffing, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is headquartered in Dallas, Texas.
About Co-Diagnostics
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for AMN Healthcare Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMN Healthcare Services and related companies with MarketBeat.com's FREE daily email newsletter.
